Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia



Status:Recruiting
Conditions:Neurology, Neurology, Neurology
Therapuetic Areas:Neurology
Healthy:No
Age Range:40 - 85
Updated:4/20/2017
Start Date:January 27, 2017
End Date:March 2020
Contact:Hannah Silverman
Email:hs2971@cumc.columbia.edu
Phone:212-305-6284

Use our guide to learn which trials are right for you!

Frontotemporal dementia (FTD) is a progressive neurodegenerative illness that affects the
frontal and anterior temporal lobes of the brain. Changes in behavior, including agitation,
aggression, and repetitive behaviors, are common symptoms in FTD. The investigators
currently do not have good medications to treat these symptoms in FTD, and the medications
the investigators use often have side effects. In this project, the investigators will test
the use of low-dose lithium, compared to a placebo pill, for the treatment of behavioral
symptoms in FTD. Lithium greatly reduces the behavioral symptoms of bipolar disorder, and
many have found low-dose lithium to be well-tolerated in patients with dementia. Lithium
appears to inhibit the creation of a protein involved in many cases of FTD called tau.

Behavioral symptoms of Frontotemporal dementia (FTD), including agitation, aggression, and
inappropriate repetitive behaviors are common, distressing to patients and caregivers, often
lead to institutionalization, and can be very difficult and expensive to treat. There is a
dearth of medication for treating these symptoms in FTD. Typically, antidepressants and
antipsychotic medications are prescribed - which low efficacy and, with the latter class,
carry serious adverse effects such as parkinsonism and increased cardiovascular-related
mortality. The investigators propose a study of the efficacy of lithium carbonate compared
to placebo in the treatment of agitation, aggression, and inappropriate repetitive behaviors
in 60 patients with FTD in a randomized, double-blind, two-arm parallel 12-week trial.
Lithium is a highly effective treatment for mania and symptoms of agitation or aggression in
bipolar disorder. It also inhibits tau aggregation and phosphorylation, leading to
considerable interest in its use as a disease-modifying treatment for tauopathies such as
FTD and Alzheimer's disease. Unfortunately, earlier trials using typical doses (i.e., doses
prescribed for treatment of bipolar disorder) showed high incidence of serious adverse
effects (including confusion and delirium). For the study proposed study the investigators
will: 1) use lower doses and lower target serum concentrations than have preceding trials
(shown in preliminary data from a Columbia study and data from other labs to be
well-tolerated) and 2) target behavioral symptoms rather than cognitive outcomes.

Inclusion Criteria:

- Age 40-85

- A diagnosis of behavioral variant FTD (bv-FTD) or semantic variant Primary
Progressive Aphasia (sv-PPA, which is generally accompanied by a behavioral
syndrome), or agrammatic/non-fluent Primary Progressive Aphasia (nfv-PPA) with
behavioral symptoms

- Neuropsychiatric Inventory (NPI) agitation/aggression subscale score ≥4 or
disinhibition subscale score ≥ 4 or repetitive behavior subscale ≥ 4 or total score ≥
6. On each subscale, a score higher than 4 represents moderate to severe symptoms

- Folstein Mini-Mental State Examination (MMSE) score 5-26/30

- An study partner (usually a family member) is required to provide information during
interviews about the patient

- Capacity to consent. Subjects without capacity to consent must have capacity to
appoint a surrogate

- Structural MRI or CT scan after symptom onset

Exclusion Criteria:

- Medical contraindication or history of intolerability to lithium, falls in the last
month, current abnormal thyroid functions (T3, T4 or thyroid stimulating hormone
(TSH); treated hypothyroidism with normal thyroid function tests will not lead to
exclusion), creatinine level > 1.5 mg/100 ml or glomerular filtration rate < 44
ml/min/1.73m2 will also lead to exclusion

- The diagnosis of bipolar disorder or schizophrenia or schizoaffective disorder

- Alcohol or substance use disorder in the prior 6 months

- Current diagnosis of other major neurological disorder, e.g., Alzheimer's Disease
(AD), stroke with residual clinical deficits, multiple sclerosis, Parkinson's
disease. Subjects with MRI or CT evidence of cerebrovascular disease but without
clinical signs of stroke will be included

- Sitting blood pressure > 150/90 mm Hg, unstable cardiac disease, severe or unstable
medical illness

- Use of medications, including diuretics, known to have adverse effects when combined
with lithium. Use of antipsychotic medications will be permitted

- Current major depression or suicidality or dangerous behavior with risk of harm to
self and others

- Corrected QT interval (QTc) interval > 460 ms at the time of baseline
electrocardiogram (EKG)

- Woman of child-bearing potential
We found this trial at
2
sites
3400 N Charles St
Baltimore, Maryland 21205
410-516-8000
Principal Investigator: Chiadi Onyike, MD
Phone: 410-550-9020
Johns Hopkins University The Johns Hopkins University opened in 1876, with the inauguration of its...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
630 W 168th St
New York, New York
212-305-2862
Principal Investigator: Edward Huey, MD
Phone: 212-305-6284
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
?
mi
from
New York, NY
Click here to add this to my saved trials